All In Biotech

Drug Trial Radar · NCT04498832

Study to Assess the Immune Response and the Safety Profile of a High-Dose Quadrivalent Influenza Vaccine (QIV-HD) Compared to a Standard-Dose Quadrivalent Influenza Vaccine (QIV-SD) in Japanese Adults 60 Years of Age and Older

Immunogenicity and Safety of High-Dose Quadrivalent Influenza Vaccine (SP0178) Administered by Intramuscular Route Versus Standard-Dose Quadrivalent Influenza Vaccine by Subcutaneous Route in Subjects 60 Years of Age and Older in Japan

Last checked: Nov 19, 2026Latest source record: Sep 23, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 2,100 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

2,100

Actual

Start

Oct 21, 2020

Primary completion

Jan 14, 2021

Study completion Jan 14, 2021

Sponsor

Lead sponsor
Sanofi Pasteur, a Sanofi CompanySanofi (SNY)
Sponsor type
Industry
First posted
Aug 5, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 60 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

Primary Objective: To demonstrate that QIV-HD induced an immune response (as assessed by hemagglutination inhibition \[HAI\] geometric mean titers \[GMTs\] and seroconversion rates) that was superior to responses induced by QIV-SD for the 4 virus strains at 28 days post-vaccination in all participants. Secondary Objective: * To describe the immune response induced by QIV-HD and QIV-SD by HAI measurement method in all participants. * To describe the safety profile of all participants in each study group.

Conditions

  • Influenza Immunization
  • Healthy Volunteers

Interventions

  • High-Dose Quadrivalent Influenza Vaccine, (Zonal Purified, Split Virus) 2020-2021 Strains (QIV-HD)Biological

    Pharmaceutical form: Suspension for injection in pre-filled syringe Route of administration: IM

  • Local Standard-Dose Inactivated Quadrivalent Influenza Vaccine, 2020-2021 Strains (QIV-SD)Biological

    Pharmaceutical form: Suspension for injection in pre-filled syringe Route of administration: SC

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Geometric Mean Titers (GMTs) of Influenza Vaccine Antibodies at Day 28Time frame: Day 28 (post-vaccination)
  2. Percentage of Participants Achieving Seroconversion Against Influenza Virus Antigens: Superiority AnalysisTime frame: Day 28 (post-vaccination)

Locations

10 sites in 1 country. Site status is shown where the registry gives one.

  • Investigational Site Number 3920005

    Fukuoka, Japan

  • Investigational Site Number 3920004

    Koganeishi, Japan

  • Investigational Site Number 3920006

    Kumamoto, Japan

  • Investigational Site Number 3920001

    Osaka, Japan

  • Investigational Site Number 3920003

    Shinjuku-Ku, Japan

  • Investigational Site Number 3920008

    Shinjuku-Ku, Japan

  • Investigational Site Number 3920009

    Shinjuku-Ku, Japan

  • Investigational Site Number 3920002

    Suita-Shi, Japan

  • Investigational Site Number 3920007

    Toshima-Ku, Japan

  • Investigational Site Number 3920010

    Yokohama, Japan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.